Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa target

besponsa target

Перейти к контенту

Главное меню:

Разное
besponsa target
About BESPONSA® | BESPONSA®, About ALL | BESPONSA®, Besponsa (Inotuzumab ozogamicin) Drug / Medicine Information, BESPONSA 1 mg powder for concentrate for solution for , FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute , Inotuzumab ozogamicin - Wikipedia, Besponsa Prices, Coupons & Patient Assistance Programs , Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, Package leaflet: Information for the user BESPONSA 1 mg .
BESPONSA is associated with a risk of liver problems and increased risk of death after stem cell transplant. BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they:. BESPONSA is the first and only therapy approved to target CD22, a specific protein that occurs on the surface of ALL cells. HOW OTHER PATIENTS RESPONDED How was BESPONSA studied?. Several different therapies are available that target specific proteins on ALL cells, such as CD19, CD22, and CD20. Stem cell transplant. A procedure that replaces the blood-forming stem cells in your bone marrow with healthy cells, restoring normal blood cell growth. CAR T-cell therapy . A gene therapy that can help your immune system to better recognize and fight your cancer, used in .
It belongs to a group of medicines called antineoplastic agents that target cancer cells. Besponsa is used to treat adults with acute lymphoblastic leukaemia (ALL). ALL is a cancer of the blood . There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment. B-cell precursor ALL is a type of cancer in which. Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medication consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.. Besponsa Prices, Coupons and Patient Assistance Programs. Besponsa (inotuzumab ozogamicin) is a member of the miscellaneous antineoplastics drug class and is commonly used for Acute Lymphoblastic Leukemia.. Besponsa (inotuzumab ozogamicin, previously CMC-544) is an approved therapy developed by Pfizer to treat adults with B-cell precursor acute lymphoblastic leukemia (ALL) whose disease has relapsed or who did not respond to standard therapy..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню